Gantacurium

DB05710InvestigationalSmall molecule

Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.

Mechanism: Pharmacologically active on Neuronal acetylcholine receptor subunit alpha-3
Curator reviewed
Primary indication: Investigated for use/treatment in anesthesia (unspecified).Curator reviewed
Formula / weight: C₅₃H₆₉ClN₂O₁₄ · 993.58 g/mol (avg)
Code names: AV-4430A · GW-280430 · GW-280430A

Resolves to

Compound

UNIIN9VK9ZO25ECAS758669-50-0ChEMBLCHEMBL1182997PubChem10772467

Structure

InChIKeyZQLDXCSTJFLRPY-RWBXLJKRSA-NSMILES

COC1=CC(C[C@@H]2C3=CC(OC)=C(OC)C=C3CC[N@@+]2(C)CCCOC(=O)C(\Cl)=C\C(=O)OCCC[N@@+]2(C)CCC3=CC(OC)=C(OC)C=C3[C@@H]2C2=CC(OC)=C(OC)C(OC)=C2)=CC(OC)=C1OC

Targets

P32297CHRNA3

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

883Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Gantacurium, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account